ISPOR’s 3rd PLENARY OF 18th ANNUAL EUROPEAN CONGRESS DISCUSSES MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Published Nov 11, 2015

PANEL REVIEWS RECOMMENDATIONS FROM ISPOR’s MCDA EMERGING GOOD PRACTICE TASK FORCE

 Milan, Italy—November 11, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress third plenary session — Recommendations from the ISPOR Multi-Criteria Decision Analysis Emerging Good Practice Task Force and Remaining Controversies — was held this morning at the MiCo – Milano Congressi in Milan, Italy. Multi-criteria decision analysis (MCDA) is an emerging new practice using a broad set of methodological approaches to assist in decision making. The topic of MCDA has become increasingly important—especially in an era of expensive but valuable health technologies—as many of today’s health care decisions require a careful assessment of the available treatment options to determine the best therapeutic choices. The plenary was moderated by Daniel Malone, PhD, RPh, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA and featured the following speakers:
Presentation of the Task Force Reports: Emerging Good Practices for Conducting MCDA:
-  Maarten J. IJzerman, PhD, Professor of Clinical Epidemiology & HTA & Vice Dean, Health & Biomedical Technology, Faculty of Science & Technology, University of Twente, Enschede, The Netherlands
-  Kevin Marsh, PhD, Senior Research Scientist & EU Director of Modelling and Simulation, Evidera, London, UK
Identification of Remaining Controversies and Solutions for Using MCDA in Health Care:
-  A. Brett Hauber, PhD, Senior Economist & Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
-   Mónica Duarte Oliveira, PhD, MSc, Associate Professor, Department of Engineering and Management, Instituto Superior Técnico, University of Lisbon, Lisbon, Portugal
Task Force Response and Discussion:
-   Nancy Devlin, PhD, Director of Research, Office of Health Economics, London, UK
-   Praveen Thokala, MASc, PhD, Research Fellow, University of Sheffield, Sheffield, UK
“Today there is tremendous interest in MCDA, but this topic was brought to ISPOR in 1999,” noted IJzerman. Marsh outlined the checklist steps for MCDA, including (1) Defining the decision problem, (2) Selecting and structuring criteria, (3) Measuring performance, (4) Scoring criteria, (5) Weighting criteria, (6) Calculating aggregate scores, (7) Dealing with uncertainty, and (8) Reporting and examining findings. Hauber pointed out that, “There is increasing demand for transparency in health care decision making and transparency is a key theme in MCDA.” And Duarte Oliveira noted that, “Delivering MCDA requires the design of the socio-technical process.” The ISPOR MCDA Task Force Report is the subject of a paper that will be published in early 2016 in Value in Health. Information on ISPOR’s MCDA in Health Care Decision Making Emerging Good Practices Task Force may be found at http://www.ispor.org/TaskForces/Multi-Criteria-Decision-Analysis-GRP.asp. Released presentations from the ISPOR 18th Annual European Congress are available at http://www.ispor.org/Event/ReleasedPresentations/2015Milan. ISPOR’s 18th Annual European Congress may be followed on social media using the hashtag #ISPORMilan.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×